Amgen Inc.

Oncology and Hematologic Malignancies

Amgen Inc. funds research across a broad oncology portfolio spanning non-small cell lung cancer, small cell lung cancer, metastatic castration-resistant prostate cancer, gastric and gastroesophageal junction cancer, colorectal cancer, melanoma, acute lymphoblastic leukemia, and solid tumors with molecular targets such as KRAS p.G12C and MTAP deletion.

  • Advanced solid tumors
  • KRAS-altered cancers
  • Small cell lung cancer
  • Prostate cancer
  • Hematologic malignancies

Its cancer research also includes biomarker-defined disease groups such as FGFR2b-overexpressing tumors, MSI-H/dMMR solid tumors, and PD-L1-negative disease.

Inflammatory and Autoimmune Diseases

The sponsor supports studies in immune-mediated disorders including atopic dermatitis, asthma, ulcerative colitis, antineutrophil cytoplasmic antibody-associated vasculitis, Behçet’s disease, juvenile idiopathic arthritis, juvenile psoriatic arthritis, and Sjögren’s syndrome.

  • Atopic dermatitis
  • Asthma
  • Ulcerative colitis
  • Vasculitis
  • Pediatric autoimmune disease

Additional interest extends to IgG4-related disease, generalized myasthenia gravis, and relapsing-remitting multiple sclerosis.

Cardiovascular and Metabolic Disorders

Amgen Inc. also funds research in cardiovascular disease, with studies in atherosclerotic cardiovascular disease, high cardiovascular risk, acute myocardial infarction, dyslipidemia, elevated lipoprotein(a), and heart failure with preserved or mildly reduced ejection fraction.

  • Atherosclerotic cardiovascular disease
  • Acute myocardial infarction
  • Dyslipidemia
  • Heart failure
  • Obesity-related cardiovascular risk

Its metabolic research includes overweight and obesity, type 2 diabetes mellitus, chronic weight management, and obstructive sleep apnea associated with excess body weight.

Neurology and Pain Disorders

The portfolio includes neurologic and pain-related conditions such as chronic migraine, episodic migraine, and relapsing-remitting multiple sclerosis, along with pediatric and adult immune-neurologic conditions.

  • Chronic migraine
  • Episodic migraine
  • Multiple sclerosis
  • Generalized myasthenia gravis

Research in this area also touches on central nervous system autoimmune disease and neuromuscular weakness.

Bone, Kidney, and Rare Disease Areas

Amgen Inc. funds studies in osteogenesis imperfecta, secondary hyperparathyroidism in pediatric patients with chronic kidney disease on hemodialysis, and other rare or specialized disorders affecting skeletal and mineral metabolism.

  • Osteogenesis imperfecta
  • Chronic kidney disease
  • Secondary hyperparathyroidism
  • Thyroid eye disease

Its research also includes prurigo nodularis and moderate to severe plaque psoriasis, reflecting interest in chronic dermatologic and inflammatory conditions.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1
    Investigated drugs:
    Belgium Czechia Denmark Estonia Finland Germany +5
  • Comparison of Sotorasib versus Docetaxel in Previously Treated Non-Small Cell Lung Cancer Patients with KRAS p.

    Not recruiting

    3 1 1 1
    Investigated diseases:
    France Germany Greece Italy The Netherlands Poland +2
  • Study of Sotorasib Alone and Combined with Pembrolizumab in Adult Patients with Advanced Solid Tumors Having KRAS p.

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Austria Belgium France Greece Hungary Portugal +2
  • Study of Tarlatamab for Patients with Limited-Stage Small-Cell Lung Cancer After Chemoradiotherapy

    Not recruiting

    3 1 1
    Investigated diseases:
    Austria Belgium Bulgaria France Germany Greece +6
  • Study comparing tarlatamab with topotecan in patients with relapsed small cell lung cancer after first-line chemotherapy

    Not recruiting

    3 1 1 1
    Austria Belgium Czechia Denmark France Germany +9
  • Study of Tarlatamab and Durvalumab compared to Durvalumab alone for patients with extensive stage small cell lung cancer

    Not recruiting

    3 1 1 1
    Austria Belgium Bulgaria Czechia Denmark France +10